

# INPLASY PROTOCOL

To cite: Gupta et al. The relative efficacy of monotherapies for dermatophyte toenail onychomycosis: a systematic review with quantitative syntheses of the evidence base. Inplasy protocol 202240157. doi: 10.37766/inplasy2022.4.0157

Received: 27 April 2022

Published: 27 April 2022

**Corresponding author:**  
Aditya Gupta

agupta@mediproberesearch.com

**Author Affiliation:**  
Mediprobe Research Inc.

**Support:** Self-financed.

**Review Stage at time of this submission:** Formal screening of search results against eligibility criteria.

**Conflicts of interest:**  
None declared.

## The relative efficacy of monotherapies for dermatophyte toenail onychomycosis: a systematic review with quantitative syntheses of the evidence base

Gupta, AK<sup>1</sup>; Venkataraman, M<sup>2</sup>; Bamimore, MA<sup>3</sup>.

**Review question / Objective:** The objective of the proposed study is to examine the relative efficacy of monotherapies for dermatophyte toenail onychomycosis, as per mycological, clinical and/or complete cure rates.

**Condition being studied:** Dermatophyte toenail onychomycosis.

**Eligibility criteria:** A randomized or observational study with at least one arm investigating the efficacy of antifungal monotherapy for dermatophyte toenail onychomycosis in terms of mycological cure, complete cure and/or clinical cure.

**INPLASY registration number:** This protocol was registered with the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) on 27 April 2022 and was last updated on 27 April 2022 (registration number INPLASY202240157).

### INTRODUCTION

**Review question / Objective:** The objective of the proposed study is to examine the relative efficacy of monotherapies for dermatophyte toenail onychomycosis, as per mycological, clinical and/or complete cure rates.

**Rationale:** Many individuals are affected by onychomycosis, a term that corresponds to fungal infection of the nails; furthermore, the infections occur more often in the nails of the toes than in those of the fingers. Having onychomycosis is correlated with a decreased quality of life. Numerous therapeutic agents exist for the management of toenail onychomycosis,

---

and investigating the relative efficacy thereof would have great clinical and research implications.

**Condition being studied:** Dermatophyte toenail onychomycosis.

## METHODS

**Search strategy:** The literature was systematically searched through the PubMed database.

**Participant or population:** Our population of interest is healthy immunocompetent adults (i.e., aged 18 years or above) with dermatophyte toenail onychomycosis. Participants can be of any sex/gender and race/ethnicity.

**Intervention:** Our intervention of interest is any monotherapy used for treating dermatophyte toenail onychomycosis.

**Comparator:** Comparators can be any of the following:(1) vehicle/placebo & (2) other monotherapies for treating dermatophyte toenail onychomycosis.

**Study designs to be included:** Evidence will be gathered from randomized and observational studies.

**Eligibility criteria:** A randomized or observational study with at least one arm investigating the efficacy of antifungal monotherapy for dermatophyte toenail onychomycosis in terms of mycological cure, complete cure and/or clinical cure.

**Information sources:** Searches were conducted in PubMed.

**Main outcome(s):** Mycological, clinical and/or complete cure.

**Data management:** Data will be organized into spreadsheets.

**Quality assessment / Risk of bias analysis:** Quality of evidence within studies will be assessed using Cochrane Collaboration's risk of bias (RoB) tool; evidence quality across studies will be evaluated using the

**Grading of Recommendations, Assessment, Development and Evaluations (GRADE) framework.**

**Strategy of data synthesis:** The evidence we gather after the data extraction stage will guide the logistics of all quantitative analyses.

**Subgroup analysis:** If there is sufficient data, clinically meaningful subgroup analyses will be done.

**Sensitivity analysis:** None.

**Language:** Only evidence in English language will be included.

**Country(ies) involved:** Canada.

**Keywords:** dermatophytosis; antifungal therapy; network meta-analysis; mycological cure.

**Contributions of each author:**

Author 1 - Aditya Gupta.

Author 2 - Maanasa Venkataraman.

Author 3 - Mary Bamimore.